Takeda goes all in with build-to-buy play, picking up Maverick and its clinic-ready T cell engagers for $525M
09 Mar 2021
As soon as Takeda and Maverick tied the bow on a $125 million pact in 2017, a countdown was set off: The pharma giant — then in the process of overhauling its R&D operations and assembling an immuno-oncology pipeline — had five years to watch and lend a hand in its little biotech partner’s preclinical work on T cell engagers and decide whether to snap it up or not.
It didn’t end up taking that long.
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.